Jump to navigation

Home

Search form

Main menu

  • HOME
  • ABOUT
    • Founder
    • Optimata Team
    • Publications
    • Awards Grants and Projects
    • Exhibitions and Conferences
  • PREDICARE
    • Current Standard of Care
    • The PrediCare Product
    • Optimizing Treatment Switch
    • Technology
  • CONTACT US
  • SEARCH

Change Lang

  • 简体中文 简体中文
  • English English
title=

Awards Grants and Projects

ABOUT

  • Founder
  • Optimata Team
  • Publications
  • Awards Grants and Projects
    • Optimata’s CSO Zvia Agur Named Finalist for EU Prize for Women Innovators 2016
    • MEL-PLEX
    • DDMoRe
    • APO-DECIDE
    • Office of the Chief Scientist
  • Exhibitions and Conferences
  • 简体中文 简体中文
  • Optimata’s CSO Zvia Agur Named Finalist for EU Prize for Women Innovators 2016

    Nine outstanding women entrepreneurs who have brought their breakthrough ideas to the market are entering the final stage of the EU Prize for Women Innovators 2016. The shortlist, which includes Optimata’s Founder and CSO, Professor Zvia Agur, was announced today by the European Commission. The contestants have all founded or co-founded successful companies based on their innovative ideas.

    READ MORE
  • MEL-PLEX

    Optimata recently became a partner in the new MELanoma disease comPLEXity (MEL-PLEX) research program, aimed at applying translational cancer systems biology and cancer systems medicine to study novel treatment options for personalized, patient-tailored melanoma therapies.

    READ MORE
  • DDMoRe
    Optimata is a participant in the Drug Disease Model Resources (DDMoRe) consortium, which was founded in 2011 by pharma partners, academics and SMEs across Europe. DDMoRe develops a public drug and disease model repository supported by an open source interoperability framework which will provide access to existing and future modeling tools.
    READ MORE
  • APO-DECIDE

    Optimata is a member of the Apoptosis Modeling for Treatment Decisions in Colorectal Cancer (APO-DECIDE) consortium, which tackles the problem of chemotherapy resistance in colorectal cancer.

    READ MORE
  • Office of the Chief Scientist

    Optimata was awarded a grant from the Office of the Chief Scientist of the Israeli Ministry of Commerce and Industry (OCS) for the development of Optimata Virtual Patient (OVP).

    READ MORE
© Optimata 2014
Concept
Site by